Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI) -- Ignore unavailable to you. Want to Upgrade?

To: Thomas M. who wrote (468)	10/9/1999 11:56:00 AM
From: OldAIMGuy	Read Replies (1) \| Respond to of 1154

Hi Thomas, Yes, GENE and CRIC before the name change have had their ups and downs. No startup biotech here, but a solid science outfit. Unfortunately not glamorous enough to attract much attention in recent years. Much has been discussed about GENE's abilities to perform the tasks they set out to do. They're good. However, they don't seem to select the tasks that interest the investment community. The attempt has always been to collaborate with partners in the developement of the human genome model and to locate genetic disorder sites that can then be treated with gene therapy. All sounds good. For years, GENE (and CRIC before) had managed to follow the above game plan. However, because of their relative obscurity, they were always negotiating the collaborations with what has been termed a "weak hand." As they gained experience and showed their abilities it was assumed that they would eventually gain a greater share of the rewards of their efforts in these collaborations. This has been true to a certain extent, but not as much as the expectations of the investment community. Although their science remains top notch, they've been somewhat left behind. They continue to manage their business in a conservative fashion and hit their targets on the projects they have. But you can imagine what the BioTech analysts are saying about this latest news article: "MOUSE DNA? Who gives a rat's butt about MOUSE DNA?" In any case, I'm keeping my position in GENE mainly because it's profitable and I hate to sell out and pay tax when I've not realized the perceived potential. It's not the foundation of my "investment pyramid" but more towards the very top. Speculative in one sense and conservative in another. Who knows? Maybe they'll cure cancer in mice!! Best regards, Tom